Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Mindfulness and Biofeedback for Anxiety Disorders

NCT: NCT07628153 · COMPLETED

NCT IDNCT07628153
StatusCOMPLETED
Start Date2022-07-11
Completion2025-02-24
SponsorI.M. Sechenov First Moscow State Medical University (OTHER)
First posted
Last updated

Brief Summary

This randomized controlled trial compared the effectiveness of a 10-day mindfulness training program using adaptive biofeedback (BFB) versus medication therapy (escitalopram 10 mg/day) versus combined treatment (BFB + medication) in inpatients with anxiety disorders (ICD-10 F40/F41). The primary outcomes were changes in anxiety (Hamilton Anxiety Rating Scale, HARS) and mindfulness (Five Facet Mindfulness Questionnaire, FFMQ) from baseline to post-treatment and at one-month follow-up.

Frequently Asked Questions

What is Mindfulness and Biofeedback for Anxiety Disorders?

Mindfulness and Biofeedback for Anxiety Disorders is a clinical trial registered under NCT07628153. Current status: COMPLETED.

What is the status of NCT07628153?

The current status of NCT07628153 (Mindfulness and Biofeedback for Anxiety Disorders) is: COMPLETED.

When did Mindfulness and Biofeedback for Anxiety Disorders start?

Mindfulness and Biofeedback for Anxiety Disorders started on 2022-07-11.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.